An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
EPR-Technologies is pursuing development of an unprecedented standard of emergency care when CPR fails
Tislelizumab is now approved in nine indications in China
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
Subscribe To Our Newsletter & Stay Updated
